ArticleFrontiers in oncology2025

Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system.

Jin Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.